Skip to main content
Premium Trial:

Request an Annual Quote

Second Genome: Joseph Dal Porto

Joseph Dal Porto has been appointed as CSO of Second Genome. Previously, he was VP at Pfizer's emerging science & innovation division and site head of Pfizer's Centers for Therapeutic Innovation. Prior to that, he was a cofounder and director of preclinical research and development at Modus BioMedicine, a spinout from Roche. Dal Porto holds a PhD in microbiology and immunology from the University of Maryland School of Medicine and a BS in biochemistry from Johns Hopkins University.

The Scan

Denisovan Girl's Tooth Found in Laos

CNN reports that a tooth found in a cave north of Vientiane likely belonged to a Denisovan girl.

A Lack of Diversity in Trials

A new report from the National Academies of Science, Engineering, and Medicine examines the limited representation of diverse groups among clinical trial participants.

Another Look

A new inquiry is to be held after genetic evidence indicates that Kathleen Folbigg's children may have been at increased risk of sudden death, the Sydney Morning Herald reports.

Nucleic Acids Research Studies on ICARUS, Neighbor-seq, CADDIE

In Nucleic Acids Research this week: resource to analyze and visualize single-cell RNA-seq data, method to examine cellular interactions, and more.